Glaucoma and Ocular Hypertension Assessment and Management

Authored by , Reviewed by Dr Colin Tidy | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Chronic Open-angle Glaucoma (Causes, Symptoms, and Treatment) article more useful, or one of our other health articles.


Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve head with progressive loss of retinal ganglion cells and their axons. This leads to a progressive loss of visual field. There are typical optic nerve changes on slit-lamp examination. Glaucoma is usually associated with an intraocular pressure (IOP) above the normal range. However:

  • 20-52% (this varies between populations) of patients with glaucoma have intraocular pressure within the normal range. Patients with normal intraocular pressure who develop the characteristic changes associated with open-angle glaucoma are said to have low tension or normal-pressure glaucoma.
  • Many patients have raised intraocular pressure for years without developing the changes of glaucoma. This condition is referred to as ocular hypertension.

Prior to 1978, glaucoma was defined as intraocular pressure above 21 mm Hg in an eye (the normal range is considered to be 10-21 mm Hg with 14 being the average). More recently glaucoma has been understood as an abnormal physiology in the optic nerve head that interacts with the intraocular pressure, with the degree and rate of damage relating to both factors[1] .

Types of glaucoma

There are several glaucoma subtypes, although all are considered optic neuropathies. Glaucoma may be primary or secondary to other conditions.

Primary glaucoma
This may be:

  • Congenital or acquired.
  • Open-angle or closed-angle, depending on how the aqueous outflow is impaired.
  • Closed-angle glaucoma may be:
    • Acute.
    • Chronic.
    • Intermittent.
    • Superimposed on chronic open-angle glaucoma.
  • Variants of primary glaucoma include:
    • Pseudoexfoliative glaucoma.
    • Pigmentary glaucoma.
    • Primary juvenile glaucoma.

Secondary glaucomas
These include:

  • Inflammatory glaucoma - eg, with uveitis.
  • Phacogenic glaucoma (caused by the lens - eg, capsular rupture).
  • Secondary to any intraocular haemorrhage.
  • Traumatic.
  • Neovascular (eg, rubeosis iridis).
  • Steroid-induced.
  • Associated with ocular tumours.

Absolute glaucoma
The end stage of glaucoma is referred to as absolute glaucoma. There is no functioning vision, the pupillary reflex is lost and the eye has a stony appearance. The condition is very painful and is treated by destructive processes.

The primary problem in glaucoma is disease of the optic nerve. The pathophysiology is not fully understood, but there is a progressive loss of retinal ganglion cells and their axons. In some cases there appears to be a genetic component.

In its early stages it affects peripheral visual field only but as it advances it affects central vision and results in loss of visual acuity, which can lead to severe sight impairment and complete loss of vision.

For most types of glaucoma, optic neuropathy is associated with a raised intraocular pressure. This has given rise to the hypothesis of retinal ganglion apoptosis, whose rate is influenced by the hydrostatic pressure on the optic nerve head and by compromise of the local microvasculature. The resulting optic neuropathy gives rise to the characteristic optic disc changes and visual field loss.

However, in normal-tension glaucoma (NTG), intraocular pressure is in the normal range and this has led to other theories including vascular perfusion problems or an autoimmune component. Others have postulated that the optic nerve head is particularly sensitive in these patients, with damage occurring at much lower intraocular pressures than in normal individuals. This could explain why these patients benefit from IOP-lowering medication[4] .

In open-angle glaucoma, flow is reduced through the trabecular meshwork (whose role is absorbing aqueous humour). This is a chronic degenerative obstruction which occurs painlessly. By contrast, in acute closed-angle glaucoma the iridocorneal angle is closed by forward displacement of the root of the iris against the cornea, so that aqueous humour cannot flow from the posterior to the anterior chamber and the elevated pressure is rapid and painful.

  • Glaucoma is one of the most common eye conditions encountered in primary and secondary care.
  • Globally, glaucoma accounted for 7.7 million people with moderate or severe visual impairment in 2020. The most common overall cause was cataract (88.4 million)[5] .
  • In the UK, glaucoma is the second most common cause for registration of visual impairment. In 2013, 1,844 people were registered as blind where glaucoma was cited as the main cause or contributory cause of their visual impairment.
  • The social burden and economic burden of glaucoma are likely to increase in the future because of longer life expectancy and an ageing population[6] .
  • Primary open-angle glaucoma (POAG) is the most common type of glaucoma, accounting for over 70% of cases[7] .
  • Ocular hypertension affects 3-5% of the population over 40 years of age but only a small proportion of these people develop glaucoma[7] .
  • If glaucoma is completely untreated, progression to severe sight impairment typically takes 25-70 years from onset. Patients of African ethnicity are significantly more likely to become blind[2, 3] .

Risk factors[2, 3]

  • Raised intraocular pressure - particularly >26 mm Hg.
  • Myopia.
  • Diabetes.
  • Positive family history: incidence increases x 2-4 for those with an affected sibling.
  • Ethnicity: some ethnic groups have increased incidence of glaucoma. People of East Asian and Inuit ethnicity have an increased incidence of closed-angle glaucoma (20-40 times in the Inuit), but a low incidence of open-angle glaucoma[8] . People of African descent are three times more likely to develop open-angle glaucoma[9] .
  • Gender: women are three times more likely than men to develop angle-closure glaucoma due to their shallow anterior chambers.
  • Prolonged use of steroids.
  • Conditions which severely restrict blood flow to the eye - eg, diabetic retinopathy, central retinal vein occlusion.
  • Eye trauma.
  • Uveitis.
  • Systemic hypertension.

The onset of open-angle glaucoma is insidious and patients are often unaware that they have it. They may have severe disease despite good visual acuity. Those with more advanced disease may be aware of a shadow in their vision or a reduction in visual acuity. However, a normal visual field in one eye may mask the presence of a defect in the affected eye until the disease is fairly advanced.

Diagnosis of this silent disease is critical. If it is missed, the window of opportunity to stop progression may be lost. If it is wrongly diagnosed, inappropriate medication may be lifelong. In some cases, diagnosis is evident, particularly with the secondary glaucomas.

Patients with suspected glaucoma need a thorough ocular examination to rule out co-pathology or other possible diagnoses. Assessments are the same for glaucoma patients and those with - or suspected to have - ocular hypertension (see 'What is ocular hypertension?', below).

Initial assessment

See also the separate Examination of the Eye article.

The National Institute for Health and Care Excellence (NICE) guidance (2017) states that before referral to an eye specialist the following tests should be carried out:

  • Gonioscopy - this is a technique used to measure the angle between the cornea and the iris to assess whether the glaucoma is open-angle or closed-angle. A mirror is placed on the surface of the numbed eye to allow the operator to measure the angle directly. If a gonioscope is not available, the van Herick test should be used. The van Herick test involves comparing the depth of the peripheral anterior chamber to the thickness of the cornea, when a narrow beam is shone within the limbus at a 60° angle.
  • Corneal thickness - this influences the intraocular pressure reading. If it is thicker than usual, it will take greater force to indent the cornea and an erroneously high reading will be obtained. (The opposite is true for a thin cornea.) Corneal thickness is measured by pachymetry.
  • Tonometry - this is the objective measurement of intraocular pressure, usually based on the assessment of resistance of the cornea to indent. The normal range is considered to be 10 mm Hg to 21 mm Hg. There are various tonometers available but the most frequently used in a hospital setting is Goldmann's applanation tonometer.
  • Optic disc examination - this is key, as it is a direct marker of disease progression. Optic disc damage is assessed by looking at the ratio of the diameters of the pale centre (cup) to the overall size of the disc.The normal cup:disc ratio is 0.3, although it can be up to 0.7 in some normal people:
    • Glaucoma is suggested by an increase in cupping with time, rather than by cupping alone. Marked but stable cupping may be hereditary.
    • The intra-observer variability in optic disc evaluation has been markedly reduced by the more routine use of ocular coherence tomography (OCT), which not only produces excellent visual records but is able to provide quantification of several data including exact cup:disc ratio and areas of neuro-retinal thinning.
  • Visual fields - these can be assessed using perimetry machines which objectively document what the patient perceives in the periphery of their vision. These assessments require the co-operation of the patient and can also be affected by fatigue, spectacle frames, miosis and media opacities. Where this is not possible, the assessor will have to rely on IOPs and cup:disc ratios alone. See also the separate Visual Field Defects article.

Some of these tests involve the use of equipment that is not usually available in GP surgeries. The involvement of a community optometrist is then appropriate.

Glaucoma may affect a person's ability to drive and may mean their licence to do so is withdrawn. See the link in 'Further Reading and References' below, regarding the DVLA rules relating to ability to drive.

Monitoring

Once diagnosis is confirmed, intraocular pressures, optic disc assessment and visual fields are regularly monitored. If the central corneal thickness has been altered - eg, by laser refractive surgery or onset of corneal pathology - this will also require reassessment[10] .

Disease progression in treated glaucoma is affected by intraocular pressure (particularly peak, rather than mean, IOP) and by IOP independent risk factors[11] .

  • Definition - ocular hypertension is used where the intraocular pressure is found to be >21 mm Hg on two consecutive occasions in the absence of any detectable glaucomatous damage. It is a major risk factor for the development of glaucoma. Lowering IOP has been shown to decrease this risk.
  • Epidemiology - ocular hypertension is estimated to affect 3-5% of individuals aged over 40; about one million people in England.
  • Management - the intraocular pressure, the central corneal thickness and the age of the patient will determine whether treatment is instigated or not:
    • For those who are not treated, ongoing monitoring is essential, as there is a risk of converting to POAG.
    • For those who do require treatment, this involves IOP-lowering drugs (discussed in the separate Primary Open-angle Glaucoma article).
    • There is considerable variation in practice with regard to who is treated and who is not but the NICE guidelines should reduce this variation.
    • Patients will be monitored six-monthly to yearly.
  • Outcome - the Ocular Hypertension Treatment Study found that the 'conversion rate' to glaucoma is 9% over five years in untreated patients, compared to 4.4% in treated individuals. There is no absolute way of predicting which of these patients will go on to 'convert' but risk factors include[12] :
    • Older age.
    • Higher intraocular pressure.
    • Larger cup:disc ratio.
    • Thinner central corneal thickness.

Specific treatments for glaucoma are discussed in the relevant clinical articles. However treatments include:

  • 360° selective laser trabeculoplasty (SLT), which reduces intraocular pressure by increasing the outflow of aqueous humour. This treatment is recommended by NICE[10] as the initial treatment of choice, unless it is not wanted or it is not suitable (eg, for patients with pigment dispersion syndrome), for those at risk of visual impairment within their lifetime due to:
    • Chronic open angle glaucoma (COAG).
    • Ocular hypertension (with an intraocular pressure of at least 24 mm Hg)
  • Medication, usually eye drops, to lower intraocular pressure. Medication is recommended to augment glaucoma surgery in those with advanced COAG; as an alternative to SLT for people with ocular hypertension who do not want or are not suitable for SLT; and for patients with COAG whose IOP has not been sufficiently reduced by SLT. The first-line medication recommended by NICE for chronic open angle glaucoma is a generic prostaglandin analogue. Poor compliance with medication is common. Medications include:
    • Prostaglandin analogues (PGAs) - eg, latanoprost.
    • Topical beta-adrenergic antagonists - eg, timolol.
    • Alpha-2 adrenergic agonists - eg, brimonidine.
    • Miotics - eg, pilocarpine, echothiophate.
    • Carbonic anhydrase inhibitors - eg, dorzolamide.
  • Trabeculectomy - removal of part of the trabecular meshwork.
  • Canaloplasty - uses a microcatheter to increase the drainage of Schlemm's canal.
  • Drainage implants - a flow tube is implanted into the anterior chamber and drains fluid out to an area under the conjunctiva, called a bleb.
  • Sclerectomy - a procedure similar to trabeculectomy but with additional excision of part of the sclera.

See the separate Primary Open-angle Glaucoma article for more details.

See the separate Angle-closure Glaucoma article for more details.

Normal-tension glaucoma is a subtype of the open-angle glaucomas. Patients have statistically normal IOPs but modification of the intraocular pressure remains the best established treatment approach. There is increasing evidence that IOP independent factors such as vascular dysregulation contribute to the pathology.

  • Nature - glaucomatous optic neuropathy with an open iridocorneal angle, in the absence of a raised mean intraocular pressure on diurnal testing.
  • Risk factors - include old age, female gender. May be associated with the Raynaud's phenomenon, migraines, paraproteinaemia.
  • Management - as for POAG, with the aim to reduce intraocular pressure by 30%. It is also recommended that systemic blood pressure be monitored over 24 hours, as normal-tension glaucoma may be associated with nocturnal systemic hypotension, and a significant nocturnal drop warrants a review of antihypertensive medication (calcium-channel blockers are preferable). When medication does not stabilise nerve damage, glaucoma-filtering surgery is the best treatment. Further research is ongoing.
  • Outcome - there is often a delay in diagnosis, resulting in more advanced visual field defects. Patients with unilateral defects have a 40% chance of developing defects in the fellow eye over five years.

Several eye disorders lead to an increase in intraocular pressure sufficient to present a risk to optic nerve structure and function. These secondary glaucomas cause a reduction in outflow of aqueous humour, caused by inflammatory debris, intraocular haemorrhage and growth of new blood vessels in the angle (neovascular glaucoma) resulting from ocular vascular diseases of the eye[14] .

  • Neovascular glaucoma:
    • This is a serious condition which arises as a result of iris neovascularisation (rubeiosis iridis).
    • It occurs following episodes of hypoxia as may occur in ischaemic retinal vein occlusion, advanced diabetic eye disease, central retinal artery occlusion, intraocular tumours, and long-standing retinal detachment, and where there has been chronic intraocular inflammation.
  • Pseudoexfoliative (PXF) glaucoma, also called exfoliative glaucoma:
    • This arises secondary to pseudoexfoliation syndrome, whereby a dusty grey deposit of extracellular amyloid-like material is deposited on the anterior lens capsule, the zonules, and the ciliary body, and in the trabecular network, so clogging the latter up.
    • It is more likely to occur in older (≥40-year-old) females.
  • Pigmentary glaucoma:
    • Pigment deposits from the posterior surface of the iris block the drainage system as with PXF.
    • It is more likely to occur in young (20- to 40-year-old), male, Caucasian myopes.
  • Exposure to corticosteroids can lead to secondary glaucoma.

Initial treatment for secondary glaucoma is to stabilise or inhibit the underlying disorder. For neovascular glaucoma, this therapy can be laser treatment for the retina and injection of inhibitors of vascular endothelial growth factor. Glaucoma related to PXF and pigment dispersion syndrome is managed with drugs and possibly laser treatment or surgery. Neovascular glaucoma involves panretinal photocoagulation and possibly retinal surgery.

The outcome is usually good, although patients with rubeiotic glaucomas tend to fare badly, as they by definition have advanced ocular comorbidity to have developed rubeiosis iridis.

See the separate Congenital Primary Glaucoma article for more detail.

  • Inflammatory glaucoma - this difficult condition presents with fluctuating IOPs and a ciliary body shutdown. It is the most common cause of severe sight impairment in children and young adults with chronic anterior uveitis. Steroid responders (a rise in intraocular pressure in response to steroid treatment for the inflammation itself) present the most tricky management issues. Treatment is broadly drug-based but severe cases may require surgery too.
  • Lens-related glaucoma - the lens may either cause a phacolytic glaucoma (a hypermature cataract sheds proteins which clog up the drainage system) or phacomorphic glaucoma (where the lens swells and bulges forward, compressing the trabecular meshwork). Both need prompt cataract surgery, although this is associated with a greater risk of complications than routine cataract surgery.
  • Traumatic glaucoma - red blood cells can block the trabecular meshwork (this is particularly the case in patients with sickle-cell haemoglobinopathies); angle recession (where blunt trauma ruptures the face of the ciliary body and damages the trabecular meshwork) also results in glaucoma in 6-9% of patients over a ten-year period.
  • Iridocorneal endothelial (ICE) syndrome - this frequently unilateral condition (typically affecting young- to middle-aged women) is characterised by iris abnormalities which are associated with glaucoma in 50% of cases. Treatment is medical and surgical.
  • Glaucoma in phacomatoses - Sturge-Weber syndrome is associated with early presentation of patients with glaucoma (60% within the first two years of life) and neurofibromatosis-1 patients may also (uncommonly) present with unilateral, congenital glaucoma.
  • Iridocorneal dysgenesis - this can arise in a number of conditions (Axenfeld-Rieger syndrome, Peters' anomaly, aniridia) and is variously associated with glaucoma, the management of which lies within the remit of specialised units.
  • Ghost cell glaucoma - degenerate erythrocytes left behind after a vitreous haemorrhage (± cataract surgery) and hyphaema may block up the trabecular meshwork so giving rise to glaucoma. These patients benefit from medical treatment but may require irrigation of the anterior chamber.
  • Glaucoma in cavernous sinus fistula - secondary glaucoma may come about as a result of raised episcleral venous pressure (resulting from a generalised increase in orbital venous pressure) impairing the aqueous outflow. If there is anterior segment ischaemia, neovascularisation may also complicate things. Medical treatment is required until the shunt resolves or is treated.
  • Glaucoma in intraocular tumours - development of glaucoma depends on the site of the tumour but it occurs in about 5% of affected eyes.
  • Glaucoma in ciliochoroidal detachment - in the event of a detachment of the ciliary body or choroid, there is an anterior displacement of the lens-iris complex resulting in shallow iridocorneal angles which may close off. Treatment is medical and surgical.
  • Glaucoma in epithelial ingrowth - occasionally, after anterior segment trauma (including surgery), conjunctival and corneal epithelial cells migrate from the external surface of the eye, through the wound and grow across the structures within. This may block off the aqueous outflow. Treatment involves surgery and cryotherapy.
  • Glaucoma in iridoschisis - this is a rare condition in which the iris atrophies. It is associated with glaucoma in 90% of cases. Laser treatment is necessary, followed by drug treatment.

Further reading and references

  1. Kwon YH, Fingert JH, Kuehn MH, et al; Primary open-angle glaucoma. N Engl J Med. 2009 Mar 12360(11):1113-24. doi: 10.1056/NEJMra0804630.

  2. Heijl A, Buchholz P, Norrgren G, et al; Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol. 2013 Aug91(5):406-12. doi: 10.1111/j.1755-3768.2012.02492.x. Epub 2012 Oct 16.

  3. Broman AT, Quigley HA, West SK, et al; Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008 Jan49(1):66-76. doi: 10.1167/iovs.07-0866.

  4. Anderson DR; Normal-tension glaucoma (Low-tension glaucoma). Indian J Ophthalmol. 2011 Jan59 Suppl:S97-101. doi: 10.4103/0301-4738.73695.

  5. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7. Epub 2020 Dec 1.

  6. Quartilho A, Simkiss P, Zekite A, et al; Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye (Lond). 2016 Apr30(4):602-7. doi: 10.1038/eye.2015.288. Epub 2016 Jan 29.

  7. King A et al; Glaucoma BMJ. 2013 Jun 11346:f3518. doi: 10.1136/bmj.f3518.

  8. Wojciechowski R, Congdon N, Anninger W, et al; Age, gender, biometry, refractive error, and the anterior chamber angle among Alaskan Eskimos. Ophthalmology. 2003 Feb110(2):365-75.

  9. Wise LA, Rosenberg L, Radin RG, et al; A prospective study of diabetes, lifestyle factors, and glaucoma among African-American women. Ann Epidemiol. 2011 Jun21(6):430-9. doi: 10.1016/j.annepidem.2011.03.006.

  10. Glaucoma: diagnosis and management; NICE Guidelines (2017 - last updated January 2022)

  11. De Moraes CG, Juthani VJ, Liebmann JM, et al; Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol. 2011 May129(5):562-8. doi: 10.1001/archophthalmol.2011.72.

  12. Kass MA, Heuer DK, Higginbotham EJ, et al; The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun120(6):701-13

  13. Song BJ, Caprioli J; New directions in the treatment of normal tension glaucoma. Indian J Ophthalmol. 2014 May62(5):529-37. doi: 10.4103/0301-4738.133481.

  14. Quigley HA; Glaucoma. Lancet. 2011 Apr 16377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.

  15. Dietze J, Blair K, Havens SJ; Glaucoma

  16. Yadav P; Glaucoma Related to Ocular and Orbital Tumors, IntechOpen, 2021

newnav-downnewnav-up